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We examined ranges of A1C useful for identifying persons at high risk for diabetes prior to
preventive intervention by conducting a systematic review. From 16 included studies, we found
that annualized diabetes incidence ranged from 0.1% at A1C 5.0% to 54.1% at A1C 6.1%.
Findings from 7 studies that examined incident diabetes across a broad range of A1C categories
showed 1) risk of incident diabetes increased steeply with A1C across the range of 5.0 to 6.5%;
2) the A1C range of 6.0 to 6.5% was associated with a highly increased risk of incident diabetes,
25 to 50% incidence over 5 years; 3) the A1C range of 5.5 to 6.0% was associated with a
moderately increased relative risk, 9 to 25% incidence over 5 years; and 4) the A1C range of 5.0
to 5.5% was associated with an increased incidence relative to those with A1C 5%, but the
absolute incidence of diabetes was less than 9% over 5 years. Our systematic review demon-
stratedthatA1Cvaluesbetween5.5and6.5%wereassociatedwithasubstantiallyincreasedrisk
for developing diabetes.
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T
he use of A1C for the identiﬁcation
of persons with undiagnosed diabe-
tes has been investigated for a num-
ber of years (1–3). A1C better reﬂects
long-term glycemic exposure than cur-
rent diagnostic tests based on point-in-
time measures of fasting and postload
blood glucose (4,5) and has improved
test-retest reliability (6). In addition, A1C
includes no requirement for fasting or for
the oral glucose tolerance test’s 2-h wait.
These advantages should lead to in-
creased identiﬁcation and more timely
treatment of persons with diabetes. Re-
cently, an American Diabetes Association
(ADA)-organized international expert
committeerecommendedtheadoptionof
theA1Cassayforthediagnosisofdiabetes
at a cut point of 6.5% (7). This cut point
was primarily derived from a review of
studies that examined the association of
A1C values with incident retinopathy,
andsomeofthemostinﬂuentialdatawere
obtained from recently published pro-
spective studies. Retinopathy was chosen
as the ultimate criterion because it is
among the main complications of diabe-
tes. Identiﬁcation of the point on the A1C
distribution most closely related to future
retinopathy will identify persons in the
greatest need of interventions for the pre-
vention of diabetes complications.
In addition to utility and conve-
nience, A1C could help identify persons
at increased risk of developing diabetes.
Thisisanimportantpublichealthpriority
since a structured lifestyle program or the
drug metformin can reduce the incidence
ofdiabetesbyatleast50and30%,respec-
tively (8). Ideally, selection of diagnostic
cut points for pre-diabetes would be
based on evidence that intervention,
when applied to the high-risk group of
interest,resultsnotonlyintheprevention
of diabetes but also later complications.
However,currentlytherearenotrialsthat
can provide data to determine the ideal
method for deﬁning cut points. In the ab-
senceofsuchdata,expertcommitteeshad
to rely on information about the shape of
risk curves for complications such as ret-
inopathy. Previous expert committees as-
sembled to address this issue have noted
thatthereisnocleardifferenceinretinop-
athy risk between different levels of im-
paired glucose tolerance (7). We are
unaware of published prospective studies
of adequate sample size or duration that
have followed people in various pre-
diabetic categories across the full span of
time until complications developed. In
the absence of informative trials (as well
as prospective studies), the studies that
measure A1C at baseline and incident di-
abetes may provide the deﬁnitions of
high-risk states.
To better deﬁne A1C ranges that
mightidentifypersonswhowouldbeneﬁt
from interventions to prevent or delay
type 2 diabetes, we carried out a system-
aticreviewofpublishedprospectivestud-
ies that have examined the relationship of
A1C to future diabetes incidence.
RESEARCH DESIGN AND
METHODS
Data sources
We developed a systematic review proto-
col using the Cochrane Collaboration’s
methods (9). We formulated search strat-
egies using an iterative process that in-
volved medical subject headings and key
search terms including hemoglobin A,
glycated, predictive value of tests, pro-
spective studies, and related terms (avail-
able from the authors on request). We
searchedthefollowingdatabasesbetween
database establishment and August 2009:
MEDLINE, Embase, the Cumulative In-
dex to Nursing and Allied Health Litera-
ture (CINAHL), Web of Science (WOS),
and The Cochrane Library.
Systematic searches were performed
for relevant reviews of A1C as a predictor
of incident diabetes. Reference lists of all
the included studies and relevant reviews
were examined for additional citations.
We attempted to contact authors of orig-
inal studies if their data were unclear or
missing.
Study selection and data abstraction
We searched for published, English lan-
guage, prospective cohort studies that
used A1C to predict the progression to
diabetes among those aged 18 years.
We included studies with any design that
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point or categories—and incident diabe-
tes. Titles and abstracts were screened for
studies that potentially met inclusion cri-
teria, and relevant full text articles were
retrieved. X.Z. and W.T. reviewed each
article for inclusion and abstracted, re-
viewed,andveriﬁedthedatausingastan-
dardized abstraction template. If A1C
measurement was standardized by the
National Glycohemoglobin Standardiza-
tion Program (NGSP) and both standard-
izedandunstandardizedA1Cvalueswere
reported, standardized values were used
in the analyses. A sensitivity analysis,
however, was conducted using both stan-
dardizedandunstandardizedA1Cvalues.
Relative measures of diabetes incidence
including relative risk, odds ratio, hazard
ratio,likelihoodratio,andincidenceratio
were examined and cumulative inci-
dences were converted to annual inci-
dences (10). In studies reporting no
measure of relative incidence, the inci-
dence ratio was estimated as the absolute
incidence in each A1C category divided
by the incidence in the lowest A1C
category.
Data analysis and synthesis
To summarize the relationship between
A1C level and diabetes incidence over
these studies, we modeled A1C as a func-
tion of annualized diabetes incidence us-
ing the aggregate study-level data. A1C
was treated as an interval censored depen-
dent variable, incidence as an independent
variable, and study as an independent fac-
tor. Studies that stratiﬁed results by sex
were treated as two separate studies. A1C,
rather than diabetes incidence, was treated
as the dependent variable because we were
unaware of any method that supported in-
terval censored independent variables; in
many studies, A1C was categorized and
thus was intrinsically censored. We used a
Weibulldistribution,whichﬁtthedatabet-
ter than a normal or lognormal distribution
(results not shown). Because we did not
know the relationship’s correct functional
form,weﬁtamodelwithnon-negativefrac-
tionalpolynomialterms,whichcanapprox-
imate many functional forms. We reported
the relationship that was the mean over all
studies and calculated pointwise 95% con-
ﬁdence limits for the curve. A sensitivity
analysis to assess the lab-to-lab variation in
A1C measurements was conducted and, to
determine if any individual study substan-
tially inﬂuenced our results, we reﬁtted the
curve, omitting data from each study one
study at a time. Modeling was conducted
using SAS (version 9.1.3; SAS Institute,
Cary, NC) PROC LIFEREG.
RESULTS
Description of study participants
In total, 16 studies (11–26) fulﬁlled our
inclusion criteria (Fig. 1). The reviewed
studiesincluded44,203totalparticipants
(range 27 to 26,563) and the follow-up
interval averaged 5.6 years (range 2.8
to 12 years) (Table 1). Overall, the mean
age among 15 studies reporting baseline
age was 53.4 years (SD 7.2) (11–24,26).
One study population was exclusively fe-
male (22) and another was exclusively
male (24); other study populations were
mixed and contained 69.0% female, on
average. Mean baseline A1C and fasting
plasma glucose among the studies were
5.2% (range 4.4 to 6.2%) and 5.4 mmol/l
(range 5.1 to 5.7 mmol/l), respectively
(11,14–16,19,21,24).
Ten studies (11,12,14,18,20,21,23–
26) reported that A1C was measured by
high-performance liquid chromatogra-
phy, three (15,19,22) used other meth-
ods,andthree(13,16,17)didnotprovide
information about A1C measurement.
A1C values in three studies (11,24,25)
were standardized by the NGSP, one (22)
bytheInternationalFederationofClinical
Chemists, and another (21) by the Swed-
ish MonoS Standard. The A1C values
standardizedbytheSwedishMonoSStan-
dard were very low and covered a very
narrow range (4.5 to 4.7%) and we did
not use data from this study for statistical
modeling.
Incidence of diabetes associated
with A1C levels
Among the eight studies that reported
A1C categories (11,12,17,21,22,24–26)
(Table 2), the range of A1C from 4.5 to
7.1% was associated with diabetes inci-
dences ranging from 0.1% per year to
54.1% per year. In general, studies that
categorized A1C across a full range of
A1Cvalues(11,12,17,22,24–26)showed
that 1) risk of incident diabetes increased
steeply across the A1C range of 5.0 to
6.5%; 2) both the relative and absolute
incidence of diabetes varied considerably
across studies; 3) the A1C range of 6.0 to
6.5% was associated with a highly in-
creased risk of incident diabetes, fre-
quently20ormoretimestheincidenceof
A1C 5.0%); 4) the A1C range of 5.5 to
6.0% was associated with a substantially
increased relative risk (frequently ﬁve
times the incidence of A1C 5.0%); and
5) the A1C range of 5.0 to 5.5% was as-
sociated with an increased incidence rel-
ative to those with A1C 5% (about two
times the incidence of A1C 5.0%).
Using data from these seven studies
(11,12,17,22,24–26), we modeled A1C
as a function of diabetes incidence (Fig.
2). The curve demonstrated that A1C was
positivelyassociatedwiththeincidenceof
diabeteswithachange-in-slopeoccurring
at an A1C level of about 5.5%. In other
words, when diabetes incidence in-
creased 0.3 to 1.8%, the A1C increased
from 5.0 to 5.5%, or on average about a
0.33percentagepointincreaseinA1Cper
1.0 percentage point increase in inci-
Figure 1—Study ﬂow chart.
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creased from 1.8 to 5.0%, the A1C
increased from 5.5 to 6.0%, or about a
0.16percentagepointincreaseinA1Cper
1.0 percentage point increase in inci-
dence. Furthermore, when diabetes inci-
dence increased from 5.0 to 9.5%, the
A1Cincreasedfrom6.0to6.5%,orabout
a 0.11 percentage point increase in A1C
per 1.0 percentage point increase in inci-
dence. These associations convert to a
5-year incidence of 5 to 9% across A1C
of 5.0 to 5.5%, 9 to 25% across the A1C
range of 5.5 to 6.0%, and 25 to 50%
across the A1C range of 6.0 to 6.5%. We
noted that in one very large study (22)
that used Kaplan-Meier curves to depict
the relationship between time before de-
veloping diabetes and baseline A1C val-
ues, the curves appeared to diverge
between A1C values of 5.0 to 5.4% and
5.5 to 5.9%.
Our sensitivity analyses showed that
the omission of studies other than the
Edelmanstudycreatedlittlechangeinthe
curve. Omission of the Edelman study re-
sulted in a biologically implausible curve.
However, in the range of A1C/incidence
discussed here, the difference between
the curves with/without the Edelman
studywassmall.Thus,whiletheEdelman
study was highly inﬂuential in overall
curve ﬁtting, its impact on our study’s
conclusions was minor.
Inadditiontothestudiesexamininga
full range of A1C values, three additional
studies (14,15,18) evaluated incidence
above/below a dichotomous cut point in
the5.8to6.1%range.Thesestudiesdem-
onstrated incidence estimates two to four
times as great among the higher A1C
groups and showed stronger associations
between A1C and subsequent incidence
among persons with impaired fasting
glucose.
CONCLUSIONS— This systematic
review of prospective studies conﬁrms a
strong, continuous association between
A1C and subsequent diabetes risk. Per-
sons with an A1C value of 6.0% have a
very high risk of developing clinically de-
ﬁned diabetes in the near future with
5-year risks ranging from 25 to 50% and
relative risks frequently 20 times higher
comparedwithA1C5%.However,per-
sons with an A1C between 5.5 and 6.0%
also have a substantially increased risk of
diabetes with 5-year incidences ranging
from 9 to 25%. The level of A1C appears
to have a continuous association with di-
abetes risk even below the 5.5% A1C
threshold, but the absolute levels of inci-
dence in that group are considerably
lower.
In light of recent interest in adopting
A1C for the diagnosis of diabetes, these
ﬁndings may be useful to guide policies
related to the classiﬁcation and diagnosis
of persons at high risk of developing dia-
betes prior to preventive intervention.
The progression of risk of diabetes with
A1C is similar in magnitude and shape as
previously described for fasting plasma
glucose and 2-h glucose and suggests that
A1C may have a similar application as an
indicator of future risk (27). The ideal de-
cision about what A1C cut point is used
for intervention should ultimately be
basedonthecapacityforbeneﬁtasshown
inclinicaltrials.Ourﬁndingssuggestthat
A1C range of 5.5 and 6.5% will capture a
large portion of people at high risk, and if
interventions can be employed to this tar-
get population, it may bring about signif-
icant absolute risk reduction. Given the
current science and evidence of the cost-
effectiveness of intensive interventions
conducted in clinical trials (28,29), the
use of a threshold somewhere between
5.5 and 6.0% is likely to ensure that
persons who will truly beneﬁt from pre-
ventive interventions are efﬁciently iden-
tiﬁed. It is also reassuring that the mean
A1C values of the populations from the
DiabetesPreventionProgram,theFinnish
Diabetes Prevention Study, and the In-
dian Diabetes Prevention Program,
wherein the mean A1C was 5.8 to 6.2%
and SDs of at least 0.5 percentage points,
spantherangefrom5.5to6.5%(28–30).
There was considerable variation in
Figure 2—A1C modeled as a function of annualized incidence. The dashed lines are pointwise 95% conﬁdence limits for the ﬁtted curve.
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incidence across studies stemming from
several factors. First, there was consider-
able variation in the populations studied
ranging from relatively young women
(15) to older men (23). Second, the mag-
nitude of relative risk is highly dependent
upon the overall risk of the population
and the selection of the referent group;
studies with low absolute risk and the se-
lection of a particularly low-risk referent
group will have very high relative risks
across the spectrum of A1C. Third, there
was variation in the outcome deﬁnition
with almost all studies using fasting glu-
cose of 7.0 mmol/l as the deﬁnition of
diabetes, but only approximately half of
the studies using the oral glucose toler-
ance test. Fourth, there is likely to be
some variation in relative risk because of
variation in the calculation of risk statis-
tics; studies reported relative risks, odds
ratios, and incidence ratios, and simple
presentations of incidence. Since we
lacked original data, we were unable to
optimallyconvertandstandardizeriskes-
timates across groups. Fifth, A1C assays
vary across laboratories. As indicated
above, A1C measurement was standard-
ized by NGSP only in three studies
(11,24,25), and only one study (24) re-
ported both standardized and unstand-
ardized A1C values. When we conducted
asensitivityanalysisinourmodelingA1C
asafunctionofincidenceusingbothstan-
dardized and unstandardized A1C values
from one study (24), there was the maxi-
mum likelihood that continuous curves
did not show any signiﬁcant difference.
Finally, there was variation in the choice
of cutoff points that may have inﬂuenced
the conclusions. Several studies pre-
sented in our review were not suitable for
modeling because they did not examine
incidenceofdiabetesacrossabroadrange
of A1C values. However, the conclusions
from these additional studies were gener-
ally consistent with those that examined
multiple A1C categories. For example,
studies by Ko et al. (15), Inoue et al. (14),
and Little et al. (18) used dichotomous
cut points of 5.8, 6.1, and 6.0, respec-
tively, and found that persons above the
threshold had roughly three times the in-
cidence of those below the cutoff point.
SeveralstudiesfoundthatA1Cispar-
ticularlypredictiveoffuturediabetesafter
prior stratiﬁcation of fasting plasma glu-
cose (11,14,21,24,26). This is consistent
with prior observations that elevated fast-
ing and 2-h glucose in combination indi-
cates greater risk than either fasting
plasma glucose or A1C alone. This im-
proved predictability may be a function
of reducing error variance; in other
words,conductingafollow-uptestclar-
iﬁes the group with more stable hyper-
glycemia, and is the main reason that a
second test is recommended for a full
clinical diagnosis.
Our most important limitation was
the lack of original data to model the con-
tinuous association between A1C values
and incidence. This lack of original data
required us to use a modeling approach
with which many readers are unfamiliar.
Nevertheless, our modeling of average
studies resulted in an average incidence
value of roughly 1% per year for persons
with normal A1C values, an incidence es-
timate that is consistent with numerous
other estimates of the general population.
The lack of access to raw data also pre-
vented us from conducting formal ROC
analyses of A1C cut-off points to distin-
guishbetweeneventualcases/noncasesor
to quantitatively assess the impact of vari-
ation in population characteristics on the
relationship between A1C and incidence.
Our ﬁndings could also be inﬂuenced by
the choice of outcome deﬁnition. A1C is
more apt to predict diabetes if the out-
come is also A1C-based. We did not de-
tectmajordifferencesintheA1C/diabetes
incidence association according to the
choice of glycemic test. Since identify-
ing A1C to predict diabetes deﬁned by
glycemic indicators is ultimately circu-
lar, future studies should examine the
relationship of glycemic markers and
later diabetes risk by using several gly-
cemic markers to deﬁne incident diabe-
tes, as well as to consider morbidity
outcomes.
The growth of diabetes as a national
and worldwide public health problem,
combined with strong evidence for the
prevention of type 2 diabetes with struc-
tured lifestyle intervention and met-
formin, have placed a new importance on
the efﬁcient determination of diabetes
risk. The selection of speciﬁc thresholds,
however, will ultimately depend on the
interventions likely to be employed and
thetradeoffsbetweensensitivity,speciﬁc-
ity, and positive predictive value. These
ﬁndings support A1C as a suitably efﬁ-
cient tool to identify people at risk and
should help to advance efforts to iden-
tify people at risk for type 2 diabetes for
referral to appropriate preventive inter-
ventions.
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